BofA lowered its price target on Stryker Corporation to $380 from $450 while maintaining a Buy rating on the shares. The firm cited a softer healthcare utilization environment and adopted a more conservative outlook for 2027 across the medical technology sector. The analyst also incorporated assumptions of increased inflationary pressures and reduced margin expansion potential for medtech companies, leading to lower earnings estimates for larger-cap names with exposure to procedure volumes and cost inflation.
Stryker CorporationBofA lowered price target and reduced earnings estimates due to softer healthcare utilization and inflation.